[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

Global Statistics Representing Low Endotoxin Gelatin Market Scenario

Gelatin is extracted from collagen—a non-allergen food ingredient—, which is a natural protein found in beef and pork, and sometimes fish (skin) and chicken (bones). It offers umpteen benefits, such as adjustable strength and high biocompatibility and biodegradability, which is further increasing the demand for gelatin across the medical sector. For the record, low endotoxin gelatin is derived from alkaline-treated porcine skin and is extensively used in the fields of regenerative medicine, drug delivery, medical devices, and tissue engineering research. The gelatin can also be used for creating UV-initiated and cross-linked scaffolds of any shape, which offers a wide range of mechanical properties and are suitable for many tissue engineering applications. Globally, increasing demand for better healthcare facilities and rising health care expenditure are some of the factors driving the market growth.

The global low endotoxin gelatin market is expected to reach USD 185.57 million in 2026 from USD 135.79 million in 2016 at a CAGR of 4.1% during the forecast period 2019–2026.

Technological Advancements and Rising Demand for Medical Grade Pharmaceuticals

In the last few years, the major advances in stem cell research, regenerative medicine, and transplantation have completely revolutionized the medical sector. Similarly, new techniques are being introduced for combining cells with gelatin for developing new methods for repairing injured or diseased tissues and organs, such as scaffold for cells. Additionally, gelatin is recognized as safe by the U.S. Food and Drug Administration (FDA) for food processing. It is routinely used in the clinic as a plasma expander and a stabilizer in several protein formulations, including vaccines. Moreover, gelatin offers many benefits that make them highly favored in the biomaterial segment. Recently, gelatin-based micron and submicron particles have gained huge popularity in the field of biomolecules, drug delivery, and regenerative medicine. Some of the factors driving the market growth include increasing demand for biologically derived materials for regenerative medicine, growing organ transplantations, rising technological advancement, and growing government funding for the development of advanced therapies.

Key Findings

  • Hemostatic application segment was valued at USD 96.64 Million in 2026
  • Drug Delivery and Parenteral Applications to grow at a CAGR 3.6%

Low Endotoxin Gelatin Option is Widely Used In Hemostatic Applications

Global Low Endotoxin Gelatin drug market is segmented by application.

By application, the market is further segmented into hemostatic applications, drug delivery and parenteral applications, and regenerative medicine.

Gelatin is extensively used for the manufacturing of hemostats in the form of sponges, strips, and powder or nanofibers. About 95% of the products are manufactured using acid porcine skin gelatin as it offers greater stability and better foaming properties. Similarly, lime bovine bone gelatins are also used for the manufacturing of hemostats. Globally, around 2 million people die from hemorrhage, and hemorrhage related wounds kill nearly 5 million people every year. In fact, severe bleeding accounts for about 80% of deaths in the operation theatre, which is further boosting the demand for homeostasis to stop the blood flow and promote blood clotting. However, the hemostatic solution must be used with extra care as the exposer of harmful endotoxins can trigger the immune response. Thus, low-endotoxin gelatins offer far greater safety in in-body applications like hemostatic.

Following are some of the key benefits of low-endotoxin gelatin:

  • Excellent absorption capacity
  • Biocompatible and biodegradable
  • Gelatin-based products are fast-acting and non-antigenic
  • Outstanding foaming properties
  • Easily grind-able for syringe application
  • Gelatin is generally recognized as safe (GRAS) by the USFDA
  • Complies with the U.S., European, and Japanese pharmacopeia

To address the growing demand, a number of key players are excessively manufacturing highly purified, low endotoxin gelatins, such as Nitta Gelatin, Rousselot, and Gelita. Recently, Nitta Gelatin acquired Chicago’s Vyse Gelatin to expand its product portfolio. Similarly, Rousselot Biomedical’s X-Pure is an exceptionally safe gelatin solution for in-body hemostatic. It consists of a comprehensive range of high-purity gelatins and collagens and offers a wide range of acid porcine and lime bovine gelatins.

Rising Demand for Pure And Safe Gelatin in Healthcare is a Key Factor Driving the Low Endotoxin Gelatin Market

North America is dominating the global low endotoxin gelatin market. This can be attributed to the rising demand for tissue regeneration procedures and increasing research in the application of stem cells. In the last few years, an extensive range of regenerative technologies has been updated for the repairing of diseased tissues and organs. Similarly, the rising emphasis on stem cell research in the U.S. and Canada is adding fuel to the market growth. The market is also majorly driven by the introduction of CAR-T cell therapies, development in material sciences, development of organic and inorganic substitutes, rising awareness of personalized medicine, and growing prevalence of road accidents and chronic diseases. As per the data published by the Insurance Institute for Highway Safety, in the U.S. alone, around 34,439 accidents and about 37,461 accident-related deaths occurred in 2016. 

Apart from this, the growing prevalence of bone and joint diseases and rising demand for orthopedic surgeries are also supporting the market growth. Hemorrhage is another vital factor accelerating the demand for low endotoxin gelatin as it offers greater safety and aids in stopping the blood flow.   Today, the governments and private organizations across the globe are heavily investing in R&D activities to develop and produce low endotoxin gelatin coupled with advanced technological innovations in the healthcare industry.

The Middle East and Africa have the presence of some of the fastest developing economies that remain untapped. The market is expanding progressively and is creating abundant opportunities for new product launches. Some of the factors driving the market include the increasing prevalence of road accidents and chronic diseases, rising number of surgeries, increasing geriatric population, shifting disease demographics, growing demand for effective treatment, and rising R&D activities in the field of low endotoxin gelatin. However, lack of awareness and price sensitivity are restricting the growth to some extent.

Key Players

Some of the prominent players in the global low endotoxin gelatin market include Nitta Gelatin, NA Inc., Rousselot, Nippi. Inc. and GELITA AG.

Our Report Covers

  • Historical inferences, findings & analysis of the market from 2016–2018
  • Projections and performance forecast analysis for the future from 2019–2026
  • Production and consumption point of view (POV) analysis
  • Market drivers, restraint and opportunity analysis, to define market dynamics covering industry, regulatory, innovation, technological & pricing trends
  • Comprehensive competitive landscape mapping with recent development covering market leadership, competency, sustainability, and prospects

Low Endotoxin Gelatin Market Segmentation

By Application

  • Hemostatic Applications
  • Drug Delivery and Parenteral Applications
  • Regenerative Medicine
    • Implantable Membranes
    • 3D Bioprinting
    • Stem Cell and Organoid Culturing
  • Other Applications

By Regions


  • North America
    • U.S.
    • Canada
    • Mexico
  • South America


  • U.K
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe


  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific


  • Saudi Arabia
  • South Africa
  • Kuwait
  • Rest of LAMEA

Frequently Asked Questions (FAQs)

Rising demand for pure and safe gelatin in Healthcare, increasing demand for better healthcare facilities and rising health care expenditure are the key factors expected to drive Low Endotoxin Gelatin Market during the forecast period.
In 2026 Global Low Endotoxin Gelatin Market was valued at USD 185.57 million.
Hemostatic Applications Segment is expected to be leading segment in Low Endotoxin Gelatin Market during the forecast period.
The global low endotoxin gelatin market is expected to reach USD 185.57 million in 2026 from USD 135.79 million in 2016 at a CAGR of 4.1% during the forecast period 2019–2026.
Nitta Gelatin, NA Inc., Rousselot, Nippi. Inc. and GELITA AG are the top players in Low Endotoxin Gelatin Market.
North America is expected to hold the highest market share in the Low Endotoxin Gelatin Market.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.

Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports